Abstract: A display device includes, a display panel including a first area and a bending area adjacent to the first area in a first direction, a window on the display panel and including a light blocking member, a cover panel on the display panel, and a cover spacer on the display panel. The cover panel includes, first and second cushion layers, a heat dissipation layer between the first and second cushion layers, a light blocking layer between the first and second cushion layers and overlapping the heat dissipation layer, a base film between the display panel and the first cushion layer, and an upper bonding layer between the base film and the display panel. The light blocking layer and the heat dissipation layer overlap the light blocking member, and have ends protruding further in the first direction than ends of the upper bonding layer, the base film, and the cover spacer.

Abstract: Provided is a peptide composition for preventing or treating Alzheimer's dementia. A peptide or a salt substituent thereof according to the presently claimed subject matter exhibits effects such as suppression of LPS-mediated cytokine production, suppression of LPS-induced neuroinflammation, amelioration of cognitive impairment, suppression of beta amyloid or tau protein aggregation, and suppression of neuronal loss. The polypeptide or the salt substituent thereof can permeate the blood-brain barrier, and thus, is expected to be usefully used for preventing or treating Alzheimer's dementia.

Abstract: The present invention provides: a peptide having antibacterial activity; a composition for preventing or treating sepsis comprising same; and an antibacterial composition. More specifically, the peptide according to the present invention has the excellent effects of not only suppressing the growth of bacteria but removing endotoxins derived from bacteria, thus exhibiting an excellent therapeutic effect on sepsis, and thus can be usefully used to prevent or treat sepsis. In addition, the peptide according to the present invention has selectively excellent antibacterial activity against Gram positive/negative bacteria, and thus can be usefully used in an antibacterial composition for Gram-positive/negative bacteria, or to prevent or treat various infectious diseases caused by Gram-positive/negative bacteria.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing hepatitis B, comprising: at least one oligonucleotide selected from the group consisting an oligonucleotide represented by a nucleic acid sequence of SEQ ID NO: 1, 2, or 6 or a nucleic acid sequence complementary thereto; and an oligonucleotide having at least one chemical modification on the oligonucleotide, as an active ingredient, and a method for screening a therapeutic agent for hepatitis B according to the formation of a G-quadruplex by HBV and a candidate material. The pharmaceutical composition forms a G-quadruplex with HBV and reduces cccDNA (covalently closed circular DNA) and thus can be used in the treatment or prevention of hepatitis B.

Abstract: Provided are a marker for detecting a highly pathogenic influenza virus including a protein mutant prepared by substituting the amino acids 68 and 69 of a PB1-F2 protein, a composition for detecting a highly pathogenic virus including an agent for measuring the protein mutant, and a detection kit including the same, a method for detecting a highly pathogenic virus including measuring the protein mutant, an antiviral composition against influenza A virus including an inhibitor of binding between a PB1-F2 protein in which the amino acids 68 and 69 are substituted and DDX3, and a method for screening an antiviral substance against influenza A virus.

Abstract: Provided is an antibacterial composition against carbapenem-resistant gram-negative bacteria which includes, as an active ingredient, adenylate kinase (ADK) protein derived from Mycobacterium tuberculosis. The ADK protein derived from Mycobacterium tuberculosis, according to the subject matter, has excellent antimicrobial activity against carbapenem-resistant gram-negative bacteria, and thus may be usefully used in a variety of fields as an antibacterial composition.

Abstract: The present invention relates to a composition for preventing or treating sepsis or septic shock including a Mycobacterium tuberculosis-derived adenosine kinase (ADK) protein as an active ingredient. The Mycobacterium tuberculosis-derived ADK protein according to one exemplary embodiment of the present invention has an effect of inhibit binding between the LPS and cells by binding to LPS, and also has an excellent therapeutic effect against sepsis by enhancing viability in a sepsis animal model and suppressing inflammatory response in the lung and cell death in the spleen.

Abstract: Provided are a marker for detecting a highly pathogenic influenza virus including a protein mutant prepared by substituting the amino acids 68 and 69 of a PB1-F2 protein, a composition for detecting a highly pathogenic virus including an agent for measuring the protein mutant, and a detection kit including the same, a method for detecting a highly pathogenic virus including measuring the protein mutant, an antiviral composition against influenza A virus including an inhibitor of binding between a PB1-F2 protein in which the amino acids 68 and 69 are substituted and DDX3, and a method for screening an antiviral substance against influenza A virus.

Abstract: The present invention relates to an antibacterial composition containing, as an active ingredient, adenylate kinase or adenosine kinase (ADK) protein derived from Mycobacterium tuberculosis, and a composition for preventing or treating infectious diseases. In addition, the present invention relates to a composition for preventing or treating sepsis or septic shock. Furthermore, the present invention relates to a method for preventing, improving or treating an infectious disease comprising administering the present antibacterial composition. The ADK protein derived from Mycobacterium tuberculosis according to the present invention has excellent antibacterial activity selectively against gram-negative bacteria, and thus can be favorably used as an antibacterial composition against gram-negative bacteria or for the prevention or treatment of infectious diseases caused by gram-negative bacteria.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing hepatitis B, comprising: at least one oligonucleotide selected from the group consisting an oligonucleotide represented by a nucleic acid sequence of SEQ ID NO: 1, 2, or 6 or a nucleic acid sequence complementary thereto; and an oligonucleotide having at least one chemical modification on the oligonucleotide, as an active ingredient, and a method for screening a therapeutic agent for hepatitis B according to the formation of a G-quadruplex by HBV and a candidate material. The pharmaceutical composition forms a G-quadruplex with HBV and reduces cccDNA (covalently closed circular DNA) and thus can be used in the treatment or prevention of hepatitis B.

Abstract: The present invention relates to an antibacterial composition containing, as an active ingredient, adenylate kinase or adenosine kinase (ADK) protein derived from Mycobacterium tuberculosis, and a composition for preventing or treating infectious diseases. In addition, the present invention relates to a composition for preventing or treating sepsis or septic shock. Furthermore, the present invention relates to a method for preventing, improving or treating an infectious disease comprising administering the present antibacterial composition. The ADK protein derived from Mycobacterium tuberculosis according to the present invention has excellent antibacterial activity selectively against gram-negative bacteria, and thus can be favorably used as an antibacterial composition against gram-negative bacteria or for the prevention or treatment of infectious diseases caused by gram-negative bacteria.

Abstract: The present invention relates to a composition for preventing or treating sepsis or septic shock including a Mycobacterium tuberculosis-derived adenosine kinase (ADK) protein as an active ingredient. The Mycobacterium tuberculosis-derived ADK protein according to one exemplary embodiment of the present invention has an effect of inhibit binding between the LPS and cells by binding to LPS, and also has an excellent therapeutic effect against sepsis by enhancing viability in a sepsis animal model and suppressing inflammatory response in the lung and cell death in the spleen.

Abstract: Provided is an antibacterial composition against carbapenem-resistant gram-negative bacteria which includes, as an active ingredient, adenylate kinase (ADK) protein derived from Mycobacterium tuberculosis. The ADK protein derived from Mycobacterium tuberculosis, according to the subject matter, has excellent antimicrobial activity against carbapenem-resistant gram-negative bacteria, and thus may be usefully used in a variety of fields as an antibacterial composition.

Abstract: The present invention relates to a composition for preventing or treating sepsis or septic shock including a Mycobacterium tuberculosis-derived adenosine kinase (ADK) protein as an active ingredient. The Mycobacterium tuberculosis-derived ADK protein according to one exemplary embodiment of the present invention has an effect of inhibit binding between the LPS and cells by binding to LPS, and also has an excellent therapeutic effect against sepsis by enhancing viability in a sepsis animal model and suppressing inflammatory response in the lung and cell death in the spleen.